Grifols (GRFS) Non Operating Income (2009 - 2023)
Grifols (GRFS) posted Non Operating Income of $618082.3 for Q4 2023, up 36.77% quarter-over-quarter from $451909.4 in Q4 2022, and up 36.77% year-on-year from $451909.4 in Q4 2022.
Grifols (GRFS) Non Operating Income (2009 - 2023) Analysis & Trends
Grifols (GRFS) has reported Non Operating Income for 12 consecutive years, with $618082.3 the latest figure, recorded in Q4 2023.
- Non Operating Income for Q4 2023 came in at $618082.3, up 36.77% year-over-year; the trailing twelve-month figure through Dec 2023 was -$311.3 million (up 23.21% YoY), and the FY2025 annual result was -$731.0 million, up 8.54% from the prior year.
- Non Operating Income was $618082.3 for Q4 2023 at Grifols, up from $451909.4 in the prior quarter.
- Over five years, Non Operating Income peaked at $618082.3 in Q4 2023 and troughed at -$293.8 million in Q4 2019.
- Average Non Operating Income over 4 years is -$80.9 million, with a median of -$18.6 million recorded in 2020.
- Year-over-year, Non Operating Income plunged 42.72% in 2019 and jumped 80.1% in 2020.
- Over 4 years, Non Operating Income stood at -$293.8 million in 2019, then jumped by 93.67% to -$18.6 million in 2020, then jumped by 102.43% to $451909.4 in 2022, then surged by 36.77% to $618082.3 in 2023.
- Per Business Quant data, the three most recent Non Operating Income figures were $618082.3 in Q4 2023, $451909.4 in Q4 2022, and -$18.6 million in Q1 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -65.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -294.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -2.31 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -3.49 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -138.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 75.00 Mn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 235.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -861.00 Mn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 618,082.29 |
| Dec 31, 2022 | 451,909.39 |
| Mar 31, 2020 | -18.60 Mn |
| Dec 31, 2019 | -293.75 Mn |
| Mar 31, 2019 | -93.45 Mn |
| Dec 31, 2018 | -205.83 Mn |
| Jun 30, 2018 | 47.30 Mn |
| Mar 31, 2018 | -78.08 Mn |
| Dec 31, 2017 | -242.34 Mn |
| Jun 30, 2017 | 89.46 Mn |
| Mar 31, 2017 | -70.56 Mn |
| Dec 31, 2016 | -54.20 Mn |
| Sep 30, 2016 | 66.11 Mn |
| Jun 30, 2016 | 62.82 Mn |
| Mar 31, 2016 | -75.63 Mn |
| Dec 31, 2015 | 10.45 Mn |
| Sep 30, 2015 | 69.40 Mn |
| Jun 30, 2015 | 67.39 Mn |
| Mar 31, 2015 | 83.89 Mn |
| Dec 31, 2014 | 10.34 Mn |